Thursday, February 19, 2026
medac Group exits diagnostics business to focus on pharma
Germany-based medac Group is sharpening its corporate strategy around its pharmaceutical business and is separating from its diagnostics activities. The carve-out is being implemented through a management buy-out.
Two experienced employees from the former diagnostics unit are taking over the business and will run it independently under the newly established mevida Diagnostika GmbH. The new company is headquartered in Elmshorn.
Strategic refocus
According to the company, the move is intended to strengthen core competencies by clearly separating the business areas. The decision is described as strategic rather than driven by operational or financial pressure.
Continuity for customers
mevida is taking over the employees from the former diagnostics department. The company says it will maintain continuity in the product portfolio, service levels and customer contacts.
mevida markets in vitro diagnostics, diagnostic instrument systems and research reagents, with a focus on pathology diagnostics, laboratory medicine and molecular diagnostics. Key customer groups include hospitals, office-based labs and research institutions.
